Explore our primary range of GMP-certified and raw active pharmaceutical ingredients (APIs), designed for maximum bioavailability and high stability profiles across medical applications.
Bacterial Vaginosis (BV) represents the most common cause of abnormal vaginal discharge in women of reproductive age worldwide, affecting approximately 20% to 50% of the female population depending on geography. As the established gold-standard therapeutic agent, Metronidazole acts as a powerful nitroimidazole anti-infective. It targets anaerobic pathogens (such as Gardnerella vaginalis, Atopobium vaginae, and Mobiluncus species) by disrupting helical DNA structure and inhibiting nucleic acid synthesis, while leaving beneficial Lactobacillus populations relatively intact.
In B2B global supply networks, procurement requirements for Metronidazole have surged due to rising medical access in emerging markets and standard-of-care updates by the World Health Organization (WHO) and the US CDC. Multi-national distributors require high-capacity production lines that can continuously feed supply chains with APIs (Active Pharmaceutical Ingredients) conforming to USP, BP, and EP quality monographs. Meeting these standards requires rigorous quality control processes at every point in the supply chain, ensuring product safety and efficacy from laboratory synthesis to final patient packaging.
China has established itself as the cornerstone of global pharmaceutical API production. By combining advanced industrial engineering with extensive vertical integration, Chinese chemical parks deliver structural advantages in efficiency, safety compliance, and supply chain continuity.
By producing basic starting materials like 2-methylimidazole close to API synthesis facilities, Chinese factories minimize shipping times and reduce exposure to international logistical shocks. This raw material security stabilizes prices and protects against unexpected global supply disruptions.
Modern Chinese production sites use distributed control systems (DCS) to monitor critical manufacturing variables. Precision controls over crystallization, pH, temperature, and drying phases prevent variations between batches, ensuring high purity levels across long-term supply runs.
Equipped with modern waste treatment plants, Chinese chemical zones meet strict green chemistry standards. Closed-loop recycling systems recover solvents during production, minimizing environmental impact while lowering production costs.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
By leveraging our deep network of collaborative manufacturing lines, we ensure that every batch of active ingredients conforms to international directives. We bridge the gap between complex Chinese chemical production capacities and international regulatory expectations, providing customized solutions, documentation validation, and reliable logistics support.
OUR PREMIUM PRODUCTS WILL BRING BACK THE HEALTH
Our pharmaceutical products consist of biological products, vaccines, western medicines, raw material, intermediates, medical consumables, with high quality and affordable prices. By working closely with GMP-certified manufacturing units, we enforce cleanroom audits and sample assays to guarantee that our active pharmaceutical ingredients (APIs) maintain stability over their shelf life, meeting standard guidelines across global regions.
DERIVES FROM THE NATURE TO MAINTAIN BODY HEALTH AND BALANCE WITH PURITY
Our nutritional ingredients cover several categories as plant extracts, plant oils & proteins, probiotics and other specialties, we are committed to exploring more health ingredients to support people’s health. We develop pure plant extracts that prevent degradation of bioactive elements, offering natural, clean-label raw materials for nutritional supplements and wellness formulations globally.
Serum Pharma continuously monitors developments in cutting-edge markets. We cooperate with partners on customized formulation solutions, including Pre-Mix, Co-Crystallization, and Bio-Fermentation processes.
Metronidazole is synthesized and supplied in various forms to suit different regional clinical preferences and patient profiles:
Vaginal gels (typically formulated at 0.75% concentration) provide localized delivery that targets vaginal pathogens directly. This administration route maintains therapeutic concentrations in the vaginal tissue while keeping systemic absorption low. This minimizes typical side effects of oral metronidazole, such as gastrointestinal irritation or metallic taste, which improves overall patient adherence to treatment regimens.
Solid suppositories designed to melt at body temperature are popular in European and Latin American markets. Manufacturers combine Metronidazole with lipids or water-soluble bases (such as polyethylene glycol) to ensure even distribution across the mucosal membranes. Formulators may also include lactic acid to help restore the normal acidic pH of the vagina (pH 3.8 to 4.5), supporting the recovery of beneficial lactobacilli.
Oral tablets remain the standard therapeutic choice in many public health systems due to their low manufacturing costs and straightforward administration. To protect the stomach lining, tablets are often formulated with film coatings. Global suppliers must optimize raw API particle sizes (micronization) to ensure consistent dissolution rates and predictable pharmacokinetics across different patient groups.
In cases of mixed vaginal infections, clinicians often prescribe combination therapies. Combining Metronidazole with antifungal agents (such as Miconazole Nitrate or Clotrimazole) targets both bacterial vaginosis and concurrent yeast infections (vulvovaginal candidiasis), simplifying treatment for complex patient presentations.
The regulatory landscape for anti-infective products is tightening globally. Regulatory authorities in the US and Europe demand higher transparency, requiring comprehensive documentation for chemical synthesis, impurity identification, and solvent monitoring. Buyers should evaluate suppliers based on key regulatory and operational capabilities:
Every shipment of Metronidazole must meet current compendial specifications (USP, EP, or BP). Critical requirements include low levels of individual impurities (less than 0.1%) and total related substances (less than 0.5%), verified through validated HPLC testing methods.
Adjusting the particle size distribution (PSD) of the API is essential for local formulations. Suppositories and gels require finely micronized particles (d90 < 10 microns) to prevent grit texture and ensure stable suspension within the formulation matrix.
Experienced suppliers must provide complete Common Technical Documents (CTD), active Drug Master Files (DMF), Certificates of Suitability (CEP), and declarations confirming the absence of nitrosamine impurities in the manufacturing process.
Key regulatory, chemical, and commercial details for pharmaceutical sourcing managers and product formulators.
Our Metronidazole API is manufactured to maintain a assay purity of 99.0% to 101.0% on a dried basis, in compliance with USP and EP standards. Impurity profiles, including single impurities like 2-methyl-5-nitroimidazole, are kept well below standard regulatory thresholds through advanced crystallization steps.
We conduct stability testing under zone II and zone IV conditions (long-term and accelerated aging tests) to evaluate factors like photostability, thermal stability, and moisture resistance. This data helps formulators predict product shelf life in various global climates.
Yes. We provide comprehensive documentation packages, including Drug Master Files (DMF) for target markets, GMP compliance certificates, stability validation data, and declarations regarding BSE/TSE, residual solvents, and allergen content.
Yes. We customize particle size profiles to meet specific formulation requirements. Micronization is performed using specialized air-jet milling systems to achieve target size ranges (e.g., d90 < 20μm or d50 < 5μm) while maintaining crystalline stability.
Our production partners employ in-line process analytical technology (PAT) and automated gas chromatography to monitor intermediate steps. Every final production batch undergoes testing via high-performance liquid chromatography (HPLC) to verify compliance with international impurity standards.
Read recent industry analyses, regulatory news, and breakthroughs across nutritional and pharmaceutical sectors.
Apr 24, 2026
An analysis of market trends shifting from shark-derived squalene to sustainable, plant-derived options, detailing chemical stability, bio-efficacy, and formulation benefits for skincare and pharmaceutical applications.
Learn More →
Apr 17, 2026
Reviewing the continued demand for Dexamethasone Sodium Phosphate API as a primary anti-inflammatory agent, focusing on chemical purity standards and the challenges of formulation stability.
Learn More →FDA approved Foundayo™ (orforglipron) — the world's first and only oral GLP1 weight-loss drug that can be taken without dietary restrictions, setting a record 50-day rapid approval process.
Learn More →We supply a wide range of verified raw materials, antibiotics, nutritional extracts, and functional peptides to support health and wellness industries worldwide.
